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Interleukin-4 ameliorates experimental glomerulonephritis and up-
regulates glomerular gene expression of IL-i decoy receptor. Monocytes!
macrophages and pro-inflammatory cytokines such as interleukin (IL)-1
are important in the pathogenesis of acute glomerulonephritis. The aim of
this study was to examine whether IL-4, a cytokine with anti-inflammatory
activity, could modulate glomerular inflammation and reduce injury in
vivo. Treatment with recombinant rat IL-4 in a model of anti-glomerular
basement membrane (GBM) antibody mediated glomerulonephritis in
rats reduced glomerular injury. Albuminuria was less (73% less at day 4)
and a lower proportion of glomeruli had capillary thrombi (79% less at day
4). In IL-4 treated rats, there was a moderate reduction in the number of
macrophages in the glomeruli and also suppression of pro-inflammatory
activities of the macrophages. Northern blot analysis of glomerular RNA
showed that treatment with lL-4 up-regulated mRNA levels of type tilL-i
receptor (IL-I RTII). IL-1RTII, also known as IL-i decoy receptor, may
act as a decoy molecule to inhibit the effect of IL-113. To our knowledge,
this is the first demonstration of (i) recombinant IL-4 reducing glomerular
inflammation in vivo and (ii) a treatment that increases IL-1RTII expres-
sion in association with reduction of tissue injury in vivo.
Experimental models have been used extensively to study the
pathogenesis of glomerulonephritis [1]. Accelerated nephrotoxic
nephritis in rats has proved especially useful in relating cellular
events within the glomerulus to the severity of injury [2, 3]. It is
induced by injection of heterologous anti-glomerular basement
membrane (GBM) antibodies into rats previously immunized
against the foreign IgG. This results in an early neutrophil influx
followed by more sustained macrophage infiltration, associated
with necrosis of the glomerular tuft and accumulation of inflam-
matory cells in Bowman's space [2, 4]. This model has been used
to demonstrate that the glomerular injury is both neutrophil and
macrophage dependent [21. The pro-inflammatory cytokine inter-
leukin-i (IL-i) is crucial for glomerular injury in this model [5].
In vitro studies have shown that IL-i has the potential to
increase the intensity of acute inflammation at many different
levels [6]. It promotes leukocyte accumulation by increasing
endothelial expression of adhesion molecules, including E-selec-
tin and intercellular adhesion molecule 1 (ICAM-1), and endo-
thelial release of chemotaxins [7—9]. IL-i stimulates macrophages
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to produce a wide range of mediators, including IL-i itself, tumor
necrosis factor-a (TNF-a) and the chemokines. It also activates
intrinsic glomerular cells, including mesangial cells. In vivo, local
injections of IL-i cause acute inflammation, and systemic admin-
istration exacerbates antibody mediated injury in the heterologous
phase of nephrotoxic nephritis [10]. Furthermore, continuous
infusion of the natural IL-i receptor antagonist (IL-ira) reduces
proteinuria and inhibits crescent formation in accelerated neph-
rotoxic nephritis [5]. Treatment with IL-ira also reduces inflam-
mation in other models of injury [6]. Thus, IL-i is a promising
target for therapeutic intervention.
The IL-i system includes of two agonists, IL-ia and IL-113.
They have only 26% sequence homology at the amino acid level,
but very similar three-dimensional structures [11]. IL-ia and
IL-i/3 share two receptors: the IL-i type I receptor (IL-iRTI),
which transduces the biological activities [12]; and the type II
receptor (IL-1RTII), which has a short cytoplasmic tail, lacks
detectable signaling function and acts as a decoy receptor [13, 14].
The extracellular portion of IL-1RTII is shed from the cell surface
into the fluid phase and inhibits IL-lp selectively. The importance
of IL-1RTII in limiting the severity of IL-i induced inflammation
is supported by a recent study in which IL-i induced cytokine
production was inhibited by IL-1RTII gene transfer in a fibroblast
cell line [15]. Macrophages also secrete a natural IL-i receptor
antagonist that binds to IL-1RTI and inhibits the activity of IL-I
[16, 17]. It follows that the biological activity of IL-i depends on
the relative concentration of IL-i and IL-ira, and on the relative
abundance of IL-iRTI and IL-iRTII. This has been demon-
strated in vitro using cells transfected with IL-1RTII [is], and in
vivo by administration of IL-ira in a variety of models of acute
inflammation [6].
IL-1f3 and IL-ira are both expressed in glomeruli during the
accelerated autologous phase of nephrotoxic nephritis [18]. There
is no previous report of expression of IL-1RTII in renal tissue. In
vitro studies using neutrophils and monocytes have shown that
IL-4 and lL-i3 increase expression and shedding of IL-1RTII [i3,
i9]. In addition, interleukins-4, -6, -10 and -13 and TGF-13 reduce
macrophage synthesis of IL-i, and increase the production of
IL-Ira in vitro [20—25]. These cytokines also inhibit other pro-
inflammatory properties of macrophages, including generation of
oxygen radicals and short-lived nitrogenous intermediates, secre-
tion of proteolytic enzymes, and expression of Fc receptors [26—29].
The regulatory effect of IL-4 on macrophage function led us to
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analyze the effect of IL-4 on inflammation and injury in experi-
mental glomerulonephritis. However, like most cytokines, IL-4 is
pleiotropic and has profound effects on a variety of cell types,
most notably on differentiation of T helper cell subsets [30]. IL-4
facilitates development of Th2 cells, which promote B cell re-
sponses, and suppresses development of Thi cells, which are
important for cell mediated immunity. Inherited differences in the
relative proportion or activity of Thi and Th2 cells can determine
susceptibility or resistance to infection with intracellular parasites
[31]. This effect could be of importance in autoimmune models,
for example, experimental autoimmune glomerulonephritis [32].
For this reason, we used a rat model of the accelerated autologous
phase of nephrotoxic nephritis to minimize the influence of IL-4
on lymphocyte development. The results show that acute injury in
this model was attenuated by IL-4. This was associated with a
reduction in pro-inflammatory activities of the macrophages, and
a marked increase in glomerular expression of IL-1RTII. To our
knowledge, this is the first demonstration of (i) recombinant IL-4
reducing glomerular inflammation in vivo, and (ii) a treatment
that increases IL-1RTII expression in association with reduction
of tissue injury in vivo.
METHODS
Reagents
Nephrotoxic serum, rabbit antiserum to rat GBM, was prepared
as described previously [33].
The eDNA probe for IL-1RTII was a murine IL-I receptor
sequence (a gift from Dr. J.E. Sims, Immunex Corporation,
Seattle, WA, USA) that cross hybridizes to rat IL-1RTII mRNA
[34]. The cDNA probe for rat IL-1/3 was supplied by Dr. A. Shaw
(Glaxo Institute of Molecular Biology, Geneva, Switzerland). The
cDNA probe for rat IL-ira was prepared locally by polymerase
chain reaction (PCR) amplification of the exon 4 coding region of
the rat IL-ira sequence [18]. The eDNA probe for human tubulin
kal, which was used as a control, was a 1.6 kb insert subcloned
into pSP64 plasmid [35].
Induction of accelerated autologous phase of nephrotoxic
nephritis
Male Sprague-Dawley rats were immunized by subcutaneous
injection of 1 mg normal rabbit IgG (Sigma, Poole, UK) in
Freund's complete adjuvant (Sigma). Seven days later, the rats
(weight 180 to 240 g) were injected with 1 ml of nephrotoxic
serum intravenously [2]. Rats were killed for histological studies
and RNA extraction 96 hours after induction of nephritis. Urine
was collected by placing rats in metabolic cages for 17 hours
before induction of ncphritis (baseline), and every subsequent
night. Albuminuria was quantified by rocket immunoelectro-
phoresis [10]. Leukocytes were counted from blood collected from
the abdominal aorta at the time of killing and analyzed using a
Coulter Sysmex HST counter (Luton, UK).
Administration of recombinant rat IL-4
Recombinant rat IL-4 was produced as cell culture supernatant
from a Chinese hamster ovary (CHO)-K1 cell line transfccted
with rat IL-4 eDNA (a gift from Dr. D. Fowell, MRC Immunology
Unit, Oxford, UK) [36]. The specific activity of recombinant rat
IL-4 was 2000 units per g (assessed by up-regulation of MHC
class II molecule expression in splenic B lymphocytes) [37]. The
endotoxin level was 60 pg/mi in the cell culture supernatant, as
assessed by Limulus amoebocyte lysate assay (lower limit of
detection: 50 pg/ml) using a test kit (Kabi Vitrim, Uxbridge, UK).
Eight migrograms of recombinant rat IL-4 (in 0.5 ml of cell
culture supernatant) were administered i.p. twice daily until rats
was killed on day 4. Control rats received the same volume of cell
culture supernatant from the parent CHO-Ki cell line (endotoxin
level less than 50 pg/mi).
Morphology and immunohistology
First the kidneys were perfused with PBS at 4°C through a
cannula inserted into the abdominal aorta. Samples of renal tissue
were either snap frozen in liquid nitrogen for immunohistochem-
istry, or fixed in formalin for light microscopy as previously
described [10]. Neutrophils were counted in chloroacetate ester-
ase stained sections [10]. Staining for rabbit IgG, rat IgG (AMS
Biotechnology, Oxon, UK) and C3 (Nordic Immunology, Titburg,
The Netherlands) was performed on frozen sections by direct
immunofluorescence [38]. Monocytes/macrophages were identi-
fied in frozen sections (5 tm) by indirect immunoperoxidase
staining with monoclonal antibody (mAb) ED1 (Serotec, Oxford,
UK). Monocytes/macrophages expressing sialoadhesin, a marker
of activation, were stained with mAb ED3 (Serotec) [39]. Gb-
merular capillary thrombosis was assessed in PAS stained sec-
tions. The cell infiltrate and proportion of glomeruli containing
capillary thrombi were assessed by counting 50 consecutive gb-
meruli [10]. Severity of tubular atrophy was arbitrarily graded
from — (normal) to + + +. Cell infiltrates and morphology were
assessed blindly.
Collection of tissues for mRNA studies
Glomeruli were purified from the remaining kidney tissue by
differential sieving as described previously [18]. Total RNA was
extracted from purified glomeruli using 4 M guanidine thiocyanate
solution followed by cesium chloride gradient ultracentrifugation
[18].
Northern analysis
Equal amounts of RNA were electrophoresed on a 3.2%
formaldehyde, 1 x 3-(N-morpholino) propanesulphonic acid
(MOPS) buffer (20 mrvi MOPS, 5 m sodium acetate, 1 mM
EDTA), 1% agarose gel and transferred to Genescreen plus
(New England Nuclear, Boston, MA, USA) by capillary blot using
10 >< SSC solution (1 X SSC = 15 msi trisodium citrate, 150 mM
sodium chloride). Filters were pre-hybridized for six hours at 42°C
with 200 tg/ml denatured salmon testes DNA (Sigma UK) in 50%
formamide, 1% SDS, 10% dextran sulphate, 1 M sodium chloride.
Filters were hybridized overnight at 42°C with Klenow DNA
polymerase labeled 32P-CTP eDNA probes [40] in the same
pre-hybridization solution. After hybridization with eDNA
probes, filters were washed with 1% SDS, 1 X SSC solution (twice
for 5 mm at room temperature, and twice for 30 mm at 42°C),
followed by two washes with 1% SDS, 0.1 X SSC for 30 minutes
at 42°C. The filters were then exposed to X-Omat Kodak film with
an intensifier screen at 20°C or —70°C for various durations up to
14 days. Multiple exposure times were used to ensure optimal
conditions for densitometry. Standard positive controls of RNA
purified from the spleens and lungs of rats injected with endotoxin
were included on all filters so that the results could be compared
directly. Filters were stripped of radioactivity by washing in boiling
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0.01% SDS, 0.01 >< SSC solution before repeat hybridization with
another cDNA probe. The degree of hybridization was assessed
by scanning optimally exposed autoradiographs with a Chro-
moscan 3 densitometer (Joyce Loebl, UK). Differences in RNA
loading were corrected by reference to hybridization of the
tubulin probe using the formula:
Cytokine or receptor mRNA
Tubulin mRNA
FACS analysis of glomerular single cells
Purified glomeruli were dissociated into single cells by a three
stage digestion using trypsin, DNAase and collagenase, as previ-
ously described [411. Different types of cell were identified by
immunostaining with monoclonal antibodies to surface molecules:
MRC 0X7 for Thy 1.1 (on mesangial cells); MRC OX1 for
leukocyte common antigen (CD45); MRC 0X8 for CD8; W3/25
for CD4; R73 for TCR af3; and 1F4 for CD3. 0X23 (monoclonal
antibody to human factor H) was used as an irrelevant isotype
control. Monoclonal antibodies were purchased from Serotec.
Immunostaining was analyzed by FACS (Coulter EPICS XL,
Luton, UK).
Isolation of splenic macrophages
Single cell preparations were prepared from spleens removed
from rats. Macrophages were obtained by adherence to T162 cm2
plastic tissue culture flasks (Costar, Cambridge, MA, USA) for
one hour at 37°C in Dulbecco's Modification of Eagles Medium,
DMEM (ICN Biomedical, Thame, UK), containing 100 units/ml
of penicillin and 100 jig/mI of streptomycin (Gibco BRL, Paisley,
UK). Total RNA was extracted from adherent macrophages with
4 M guanidine thiocyanate solution [42j.
Statistics
Results are presented as mean standard error. For severity of
tubular atrophy, results are presented as range and median of
arbitrary grading. Statistical significance was assessed by Wilcoxon
Rank Sum Test (2 tailed). The correlations between glomerular
macrophage infiltration, albuminuria and capillary thrombosis
were examined by linear regression.
RESULTS
Effect of in viva injection of IL-4 in normal rats
We first established that IL-4 could be administered in doses
sufficient to influence macrophage function directly in vivo. The
dosage schedule of IL-4 8 jig i.p. twice daily was selected, because
previous experiments had shown it to be well tolerated. The IL-4
group (N = 3)was treated with 8 jig IL-4 twice daily for four days,
while control rats (N = 2) received 0.5 ml CHO-Ki cell condi-
tioned medium twice daily for the same period. The IL-4 treated
rats remained healthy and did not develop albuminuria (assay
sensitivity < 0.05 mg/ml). They had normal peripheral leukocyte
counts (9.7 0.0 x 109/liter vs. 9.2 1.2 X 109/liter in control and
IL-4 groups, respectively). Their lungs, spleens and kidneys were
histologically normal at autopsy. The splenic macrophages from
IL-4 treated rats had 92% less IL-113 mRNA than those from
control rats, when challenged with LPS in vitro (data not shown).
Fig. 1. IL-4 reduces albumin excretion in accelerated autologous phase
of nephrotoxic nephritis. The treated group (•; N = 7) receivcd i.p.
injections of 8 jig recombinant rat IL-4 twice daily for four days. The
control group (; N = 10) received injections of the same volume of cell
culture supernatant from the control cell line. The IL-4 treated group had
significantly less albuminuria than the control group. *p < 0.05 and °P <
0.01.
Effect of IL-4 on glomerulonephritis
Seventeen rats with accelerated autologous phase nephrotoxic
nephritis were treated either with 8 j.rg IL-4 (in 0.5 ml of
supernatant) i.p. twice daily (N = 7), or with the same volume of
conditioned medium from untransfected CHO-Ki cells (N = 10),
until they were killed on day 4. The first dose of IL-4 was given
seven days after immunization with rabbit IgG and 2.5 hours
before induction of nephritis by injection of nephrotoxic serum.
IL-4 treatment caused reduction in albuminuria throughout the
course of the experiment; levels at day 4 were 326.4 41.2 mg/17
hours in control rats and 88.9 15.6 mg/17 hours in IL-4 treated
rats, respectively (P < 0.01; Fig. 1). The severity of histological
injury was also significantly less in IL-4 treated rats at autopsy; the
percentage of glomeruli with thrombi was 37.2 8.4 in control
rats and 7.7 2.7 in IL-4 treated rats (P < 0.01). Tubular atrophy
was more severe in control rats (median + + +, range + to + + +)
than in IL-4 treated rats (median +, range — to + +; P = 0.01;
Figs. 2 and 3). Thus, IL-4 decreased injury in accelerated neph-
rotoxic nephritis. Another experiment with 21 rats showed similar
reduction of injury following IL-4 treatment (Table 1).
Localization of rabbit nephrotoxic antibody, rat antibody and
complement
The administered rabbit anti-rat GBM antibody and the autol-
ogous rat anti-rabbit IgG were localized immunohistologically, by
direct immunofluorescence, at a similar density along rat GBM in
both IL-4 treated and control groups (data not shown). Likewise,
there was no difference in C3 deposition along the rat GBM
between the groups (data not shown). These data show that
treatment with IL-4 had no effect on nephrotoxic antibody
deposition, nor did it influence the rat antibody response against
administered rabbit antibody.
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Fig. 2. Effect of IL-4 on renal morphology four days after induction of accelerated autologous phase of nephrotoxic nephritis. (A) In control rats, there
was capillary thrombosis in the glomeruli and tubular atropy. (B) In IL-4 treated rats, there was less glomerular and tubular injury. Sections were stained
with periodic acid-Schiff (X250).
Effect of IL-4 on glomerular leukocyte infiltration
Glomerular leukocyte infiltration was quantified histologically
in renal biopsies taken at autopsy, and by flow cytometric analysis
of single cell preparations of purified nephritic glomeruli. As
expected, there were very few neutrophils in glomeruli 96 hours
after induction of nephritis, but paradoxically the number was
slightly higher in the IL-4 treated rats (not significant; Fig. 4). In
contrast, there were significantly fewer glomerular macrophages
in IL-4 treated rats: 7.0 0.5 ED1 positive cells per glomerulus in
section in control rats and 5.3 0.4 in IL-4 treated rats (P < 0.02;
Fig. 4). Another experiment showed similar results with IL-4
treatment (Table 1). Flow cytometric analysis of single cell
preparations of nephritic glomeruli was used to examine glomer-
ular leukocytes further on day 4. An increased number of CD45+
leukocytes (51.0 7.9 per glomerulus) was found in control rats,
which was 33% less (34.3 19.2 per glomerulus) in IL-4 treated
rats. However, no T cells were found in the glomeruli of control or
IL-4 treated rats (data not shown).
Glomerular macrophages and glomerular injury
We examined the relationship between glomerular macro-
phages and the severity of injury on day 4. Results from two
experiments were analyzed. In control rats, there was a strong
correlation between the number of macrophages within the
glomerulus and the amount of albuminuria (r = 0.674, P < 0.002;
Fig. 5). In control rats, there was also a significant correlation
between the number of macrophages within the glomerulus and
the percentage of glomeruli affected by capillary thrombosis (r =
0.711, P < 0.001; Fig. 6). However, these correlations were not
significant in the IL-4 treated rats (for albuminuria, r =0.458, P =
0.06; for capillary thrombi, r = 0.309, P = 0.23).
These findings suggest that IL-4 may be inhibiting pro-inflam-
matory activities of macrophages within the glomeruli. The func-
tional state of glomerular macrophages was examined by expres-
sion of sialoadhesin (recognised by mAb ED3) [39], and also by
glomerular expression of IL-1j3 and IL-ira. The number of
macrophages expressing sialoadhesin in the glomeruli was signif-
icantly lower in IL-4 treated rats than control rats. There were
1.2 0.3 ED3 positive cells per glomerulus in section in control
rats, which was reduced by 58% in IL-4 treated rats to 0.5 0.02
per glomerulus in section (P = 0.002; Fig. 4). The proportion of
ED1 positive cells which were also ED3 positive was estimated by
examining consecutive cryostat sections. The ratio was 0.17 0.03
in the control group, which was reduced to 0.10 0.01 in the IL-4
treated group (P < 0.05).
Effect of IL-4 on IL-i decoy receptor
IL-1RTII (IL-i decoy receptor), a natural inhibitor of IL-113,
may be induced by IL-4 in vitro [13]. However, there are no
reports of expression of IL-iRTII in the glomerulus. We exam-
ined mRNA for IL-I RTII by Northern blot analysis. Glomerular
mRNA for IL-i RtII (1.8 kb) was not detected in the glomeruli of
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Fig. 3. IL-4 reduces the number of glomeruli affected by capillary
thrombi in accelerated autologous phase of nephrotoxic nephritis. The
treated group (N = 7) received i.p. injections of 8 g recombinant rat IL-4
twice daily for four days. The control group (N = 10) received injections
of the same volume of cell culture supernatant from the control cell line.
The IL-4 treated group had significantly less glomerular capillary thrombi
than the control group (P < 0.01). The proportion of glomeruli affected by
capillary thrombi was assessed by counting 50 consecutive glomeruli in
section. The results are expressed as % of glomeruli counted.
Table 1. IL-4 reduces the severity of glumerulonephritis
Number of animals
control IL-4 P
10 11
Albuminuria mg/i7hr 108.0 32.6 29.7 12.8 <0.01
Capillary thrombi % glomeruli 5.89 1.5 2.2 0.9 <0.05
ED1+ macrophages/gs 4.8 0.4 3.3 0.4 <0.02
ED3+ macrophages/gs 0.89 0.06 0.52 0.05 <0.002
Results are from another experiment (spearate from the ones shown in
Figures 1—4). In this experiment, a less nephritic batch of nephrotoxic
serum was used. Results are from urine samples and histology specimens
collected 4 days after induction of nephritis. The proportion of glomeruli
affected by capillary thrombi was assessed by counting 50 consecutive
glomeruli in section. The results are expressed as % of glomeruli counted.
IL-4 treatment reduced albuminuria, glomerular capillary thrombosis and
macrophage infiltration.
any of the control rats, but was found in IL-4 treated rats (Fig. 7).
The results shown are representative of three sets of Northern
blots.
Glomerular expression of IL-1I3 and IL-ira
Glomerular RNA samples from control rats (N = 7) or IL-4
treated rats (N = 6) were analyzed for IL-113 and IL-ira. There
were no significant differences in the amount of glomerular IL-1/3
mRNA (102 39 densitometric units in control rats vs. 128 71
units in IL-4 treated rats) or IL-ira mRNA (623 135 units in
control rats vs. 803 413 units in IL-4 treated rats) at 96 hours.
Fig. 4. IL-4 reduces glomerular monocyte/macrophage infiltration in
accelerated autologous phase of nephrotoxic nephritis. The treated group(; N = 7) received i.p. injections of 8 jg recombinant rat IL-4 twice daily
for four days. The control group (I; N = 10) received injections of the
same volume of cell culture supernatant from the control cell line. The
IL-4 treated group of rats had significantly lower numbers of total
monocytes/macrophages (ED1 +; P < 0.02) and activated macrophages
(ED3 +; P = 0.002) when compared with the control group. The difference
in neutrophil count was not significant.
These results suggest that up-regulation of IL-IRTII in the
glomeruli of JL-4 treated rats may have a role in the reduction of
glomerular inflammation.
DISCUSSION
Anti-inflammatory effects of recombinant IL-4 have been dem-
onstrated in the chronic destructive phase of streptocoeeal cell
wall induced arthritis [43] and IgG immune complex-induced lung
injury in rats [441. In humans, decreased IL-4 production has been
reported in inflammatory bowel disease [451and new onset type I
diabetes mellitus [46]. IL-4 and IL-4 receptors have been detected
in the kidneys of patients and experimental animals with glomer-
ulonephritis [47—49]. However, the role of IL-4 in glomerulone-
phritis is controversial.
The present experiments were designed to examine the direct
effects of IL-4 on macrophage-dependent acute glomerular injury.
The results show that administration of recombinant IL-4 mark-
edly reduced glomerular injury, as assessed either by albuminuria
or by renal morphology. It is highly probable that this was due to
a direct effect on macrophage induced injury because: firstly,
injury from day 2 to day 4 in this model has previously been shown
to be macrophage dependent [2]; secondly, the majority of
glomerular leukoeytes by day 4 were macrophages; thirdly, the
number of glomerular macrophages in control rats correlated with
the severity of glomerular injury; and fourthly, in a small experi-
ment, we found that the severity of glomerular injury was reduced
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Fig. 5. Relationship between the number of glomerular macrophages and
albuminuria on day 4. The relationship between the number of macro-
phages (ED1+) per glomerulus in section and the severity of injury was
assessed. In rats that received control injections (0), the number of EDI +
cells correlated with albuminuria (r = 0.674, P < 0.002; thick line as the
line of regression). However, in the rats that received IL-4 treatment (A),
the correlation was not significant (thin line as the line of regression).
0 1 2 3 4 5 6 7 8 9 10
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Fig. 6. Relationship between the number of glomerular macrophages and
glomerular capillary thrombosis on day 4. The relationship between the
number of macrophages (ED 1+) per glomerulus in section and the
severity of injury was assessed. In rats that received control injections (0),
the number of ED1 + cellscorrelated with glomerular capillary thrombosis
(r = 0.711,P < 0.001; thick line as the line of regression). However, in the
rats that received IL-4 treatment (A), the correlation was not significant
(thin line as the line of regression).
Fig. 7. Northern blot showing that IL.4 up.regulates glomerular gene
expression of decoy IL.! receptor in accelerated autologous phase of
nephrotoxic nephritis. Glomerular mRNA for decoy IL-I receptor (IL-
IRTII) was detected in IL-4 treated rats but not in the control rats. Each
sample of glomerular RNA was pooled from two rats of each group
(except in the fourth lane that was from one rat only) harvested four days
after induction of nephritis. An aliquot of RNA from the lung of a rat
injected with 100 .tg of LPS was used as a positive control for hybridiza-
tion. The results are representative of three Northern blots showing
similar results.
with sheep IgG. They found that Thi responses to sheep IgG were
suppressed and that there was less injury [501. In our experiments,
the injection schedule was designed not to influence the immune
response to rabbit IgG, and the glomeruli did not contain
significant numbers of T cells in either group. Therefore, T cells
are unlikely to be involved in the effect of IL-4 in this study,
despite the well documented effects of IL-4 on T cell develop-
ment. The results are equally unlikely to be due to the anti-
inflammatory effect of IL-4 on neutrophils, because there were
slightly more glomerular neutrophils in the IL-4 treated rats.
Furthermore, administration of IL-4 does not decrease the injury
in other neutrophil dependent models of acute injury, including
the heterologous phase of nephrotoxic nephritis (Karkar, Tam
and Rees, unpublished observation), and the acute phase of
streptococcal cell wall induced arthritis [43).
In this study, the number of glomerular macrophages correlated
with the severity of glomerular injury in control rats. However,
IL-4 treatment reduced the number of macrophages only moder-
ately, in association with a marked reduction in the severity of
injury. This suggests that the inflammatory functions of glomeru-
lar macrophages were suppressed by IL-4 treatment. We chose
sialoadhesin (recognized by mAb ED3) as a functional marker,
because it is involved in the intercellular interactions of macro-
phages [51]. It is not known whether ED3+ macrophages have a
direct role in glomerular injury. However, it has been shown that
sialoadhesin positive macrophages are normally confined to lym-
phoid tissues [52], and are only found outside the lymphoid system
at sites of immune mediated injury [39]. In our experiments, 17%
of glomerular macrophages from control rats expressed siaload-
hesin, whereas the percentage of glomerular macrophages ex-
pressing sialoadhesin in IL-4 treated rats was approximately half
that of controls. The effect of IL-4 on macrophage expression of
sialoadhesin in vitro depends on the experimental conditions and
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even when IL-4 treatment was initiated 24 hours after injection
of nephrotoxic serum (Tam, Smith and Pusey, unpublished
observation).
In a recent study of accelerated nephrotoxic nephritis in mice by
Tipping et al, IL-4 therapy was initiated before pre-immunization
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the species; IL-4 suppresses murine macrophage expression of
sialoadhesin [531, but may enhance glucocorticoid induction of
sialoadhesin in rat macrophages [51. To our knowledge, this is
the first study examining the effect of IL-4 on the expression of
sialoadhesin in vivo. Modulation of the functional state of mac-
rophages may have contributed to the significant protective effect
of IL-4 treatment, in addition to the reduction of macrophage
infiltration in the glomeruli.
Despite the consistent reduction of injusy, IL-4 treatment did
not cause significant changes in glomerular IL-113 mRNA or
IL-Ira mRNA levels. This differs from studies investigating the
production of cytokines from human peripheral blood monocytes
treated with IL-4 [201. This is possibly because IL-4 may have
divergent effect on monocytes/macrophages and intrinsic glomer-
ular cells [55]. The increased glomerular IL-1RTII mRNA in the
IL-4 treated rats provides the most obvious explanation for
reduction of glomerular inflammation. This would be consistent
with the known effect of IL-4 in increasing synthesis of IL-1RTII
in vitro, and promoting release of soluble IL-1RTII [13, 14]. It is
known that IL-1RTII is expressed on monocytes and neutrophils
[13, 14]. At present, there is no information about the cell types in
the glomeruli that may be expressing IL-1RTII in IL-4 treated
rats, but we hope to clarify this issue when a specific antibody for
rat IL-1RTII becomes available. Although this study highlights
the effects of IL-4 on expression of IL-1RTII in glomerular
inflammation in vivo, the results do not exclude the involvement of
other inflammatoiy pathways. For example, IL-4 has a broad
range of potentially anti-inflammatory properties, which include
suppression of macrophage production of nitric oxide, superoxide
and metalloproteinase [26—28, 56], and stimulation of the 12/15
lipoxygenase pathway [57].
In summary, we have demonstrated that injection of recombi-
nant IL-4 reduced the severity of acute antibody-mediated gb-
merular injury. Glomerular expression of IL-i type II receptor
(IL-i decoy receptor) mRNA was up-regulated in IL-4 treated
rats. Also, the pro-inflammatory activities of macrophages were
inhibited in IL-4 treated rats. To our knowledge, this is the first
demonstration of reduction of glomerular inflammation by re-
combinant IL-4. This is also the first demonstration of increased
expression of IL-1RTII mRNA in association with a reduction in
tissue inflammation in vivo. We suggest that the increased levels of
IL-i receptor type II could at least partly counteract the effects of
glomerular IL-113. These findings support the therapeutic poten-
tial of IL-4 in the treatment of acute inflammation.
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APPENDIX
Abbreviations used in this paper are: CHO, Chinese hamster ovary;
DMEM, Dulbecco's modified Eagles medium; GBM, glomerular base-
ment membrane; ICAM-1, intercellular adhesion molecule-I; IL, inter-
leukin; IL-ira, IL-i receptor antagonist; IL-1RTI, IL-i receptor type I;
IL-1RTII, IL-i receptor type II; mAb, monoclonal antibody; Thi, T
helper cell type 1; Th2, T helper cell type 2; TNF-a, tumor necrosis
factor-a.
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